OBJECTIVES: The CYP2B6 is one of the most polymorphic CYP genes in humans that has the potential to modify the pharmacological and toxicological responses to clinically important drugs such as antimalarial artemisinin and its derivatives. The aim of the study was to determine the frequency of CYP2B6 polymorphisms in Timor malaria endemic area, East Nusa Tenggara, Indonesia where Artemisin-based Combination Therapy (ACT) has been used to treat uncomplicated malaria. METHODS: A total of 109 healthy subjects were participated in this study. CYP2B6*4, *6 and *9 polymorphisms were analyzed using PCR-RFLP to confirm the SNPs prevalence of 516G>T and 785A>G in exon 4 and 5. RESULTS: There were 96 subjects included in the analysis. In the exon 4 of CYP2B6 516G>T, the frequency of the T mutation was 37.5% (39/96), and the wildtype 27.1% (26/96). In the exon 5, CYP2B6 785A>G mutant was detected in 29.2% (28/96) of individuals, and the wildtype allele in 35.4% (34/96). The frequency of CYP2B6*9 (516G>T), CYP2B6*4 (785A>G) and CYP2B6*6 (516G>T and 785A>G) were 40.6%, 29.2% and 22.9%, respectively. The prevalence of these CYP2B6 gene polymorphisms in Timorian ethnic were higher than that in Malay, Han Chinese, Indian, and Egyptian populations. CONCLUSION: The prevalence of these CYP2B6 516G>T and 785A>G polymorphisms in Timorian ethnic is higher than that in other populations. These polymorphisms may affect the metabolism of artemisinin and its derivatives.
Alleles ; Asian Continental Ancestry Group ; Cytochrome P-450 CYP2B6* ; Exons ; Healthy Volunteers ; Humans ; Indonesia* ; Malaria ; Metabolism ; Polymorphism, Single Nucleotide ; Prevalence*

Introduction: Hyperlipidemia is a condition that may lead to many illnesses. The worldwide prevalence of hyperlipidemia is still relatively high. Lactoferrin is a glycoprotein found in mammals and fishes’ epithelial mucosa cells, also known for its protective roles. Objective: This study aims to d Objective: This study aims to discover the histopathologic changes in rat’s liver after the intervention of 100, 200, and 400 mg/kgBW lactoferrin. Method: This study involved 30 Sprague-Dawley rats divided into six groups: normal, negative control, statin-treated, dose 1, dose 2, and dose 3. The normal group was given standard feed, while the other groups were hyperlipidemic induced by a high cholesterol diet. The intervention for the statin-treated group was 1.5 mg/kgBW statin, while dose 1, 2, and 3 were respectively given 100 mg/kgBW, 200 mg/kgBW, and 400 mg/kgBW of lactoferrin. After six weeks, all rats were dissected, and the livers’ histopathologic slides were scored with Manja Roenigk scoring. Result: Lactoferrin improved the fatty liver condition. The statistical test results showed that 200 mg/kgBW of lactoferrin caused a significant change in the rats’ liver structures (p < 0.05). Conclusion 200 mg/kgBW of lactoferrin significantly improved the histopathologic structure of fatty liver
Histology